Jefferies Financial Group Inc. Invests $2.25 Million in InMode Ltd. (NASDAQ:INMD)

Jefferies Financial Group Inc. acquired a new position in InMode Ltd. (NASDAQ:INMD - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 134,500 shares of the healthcare company's stock, valued at approximately $2,246,000. Jefferies Financial Group Inc. owned about 0.19% of InMode at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Orion Capital Management LLC bought a new stake in InMode during the 4th quarter worth approximately $65,000. SBI Securities Co. Ltd. bought a new stake in shares of InMode during the fourth quarter valued at approximately $87,000. Farther Finance Advisors LLC raised its position in shares of InMode by 26.2% during the fourth quarter. Farther Finance Advisors LLC now owns 5,555 shares of the healthcare company's stock valued at $93,000 after buying an additional 1,154 shares during the last quarter. Covestor Ltd raised its position in shares of InMode by 13.9% during the fourth quarter. Covestor Ltd now owns 5,936 shares of the healthcare company's stock valued at $99,000 after buying an additional 723 shares during the last quarter. Finally, Lazard Asset Management LLC raised its position in shares of InMode by 6,128.7% during the fourth quarter. Lazard Asset Management LLC now owns 6,291 shares of the healthcare company's stock valued at $105,000 after buying an additional 6,190 shares during the last quarter. Hedge funds and other institutional investors own 68.04% of the company's stock.

Wall Street Analyst Weigh In

INMD has been the topic of several recent analyst reports. Canaccord Genuity Group reduced their price objective on shares of InMode from $17.00 to $15.00 and set a "hold" rating on the stock in a research report on Tuesday, April 29th. Needham & Company LLC restated a "hold" rating on shares of InMode in a research report on Monday, April 28th. Jefferies Financial Group reduced their price target on shares of InMode from $16.00 to $15.00 and set a "hold" rating on the stock in a research report on Monday, April 14th. Robert W. Baird cut shares of InMode from an "outperform" rating to a "neutral" rating and reduced their price target for the stock from $22.00 to $16.00 in a research report on Monday, April 28th. Finally, UBS Group reduced their price target on shares of InMode from $19.00 to $16.25 and set a "neutral" rating on the stock in a research report on Tuesday, April 29th. Seven investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $18.54.

InMode Stock Up 0.7%

Shares of INMD stock traded up $0.10 on Friday, hitting $14.69. The stock had a trading volume of 1,170,751 shares, compared to its average volume of 1,188,733. The business has a 50 day moving average price of $15.20 and a 200 day moving average price of $17.04. The company has a market cap of $928.54 million, a PE ratio of 6.25 and a beta of 2.02. InMode Ltd. has a one year low of $13.68 and a one year high of $19.85.

InMode (NASDAQ:INMD - Get Free Report) last announced its earnings results on Monday, April 28th. The healthcare company reported $0.31 EPS for the quarter, missing analysts' consensus estimates of $0.45 by ($0.14). The firm had revenue of $77.87 million during the quarter, compared to the consensus estimate of $82.21 million. InMode had a return on equity of 18.25% and a net margin of 45.91%. The business's revenue for the quarter was down 3.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.32 earnings per share. Equities research analysts expect that InMode Ltd. will post 1.75 EPS for the current year.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.